Ruxolitinib Cream for Vitiligo
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Will I have to stop taking my current medications?
The trial requires participants to stop using all treatments for vitiligo from the start of the study until the final safety follow-up visit.
Is Ruxolitinib Cream safe for humans?
How is ruxolitinib cream different from other vitiligo treatments?
Ruxolitinib cream is unique because it is a topical treatment that works by inhibiting Janus kinase 1 and 2 (proteins involved in inflammation), which helps in repigmenting the skin in people with vitiligo. Unlike some other treatments, it is applied directly to the skin, making it a non-invasive option.15678
What data supports the effectiveness of the drug Ruxolitinib Cream for treating vitiligo?
Who Is on the Research Team?
Incyte Medical Monitor
Principal Investigator
Incyte Corporation
Are You a Good Fit for This Trial?
This trial is for children with a type of skin condition called nonsegmental vitiligo, which causes loss of skin color in patches. They should have it on at least 0.5% of their face or 3% on other body parts but not more than 10% overall. Participants must stop using other vitiligo treatments during the study and if sexually active, avoid pregnancy.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ruxolitinib 1.5% cream or vehicle cream applied topically to the affected area
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ruxolitinib Cream
Ruxolitinib Cream is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Incyte Corporation
Lead Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School